KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Depreciation and Depletion: 2009-2024

Historic Depreciation and Depletion for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $46.6 million.

  • Biomarin Pharmaceutical's Depreciation and Depletion fell 2.75% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.9 million, marking a year-over-year increase of 2.63%. This contributed to the annual value of $46.6 million for FY2024, which is 15.63% up from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Depreciation and Depletion is $46.6 million, which was up 15.63% from $40.3 million recorded in FY2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Depreciation and Depletion peaked at $46.6 million during FY2024, and registered a low of $38.6 million during FY2022.
  • Over the past 3 years, Biomarin Pharmaceutical's median Depreciation and Depletion value was $40.3 million (recorded in 2023), while the average stood at $41.8 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Depreciation and Depletion dropped by 16.99% in 2020, and later climbed by 15.63% in 2024.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Depreciation and Depletion stood at $43.0 million in 2020, then increased by 7.21% to $46.1 million in 2021, then fell by 16.27% to $38.6 million in 2022, then rose by 4.40% to $40.3 million in 2023, then increased by 15.63% to $46.6 million in 2024.